The 21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients

Annals of Surgical Oncology

Volumn 22, Issue 4, 2015, Pages 1088-1094

  Jegadeesh, Naresh K ^a   Kim, Sunjin ^a,b   Prabhu, Roshan S ^a   Oprea, Gabriela M ^a   Yu, David S ^a   Godette, Karen G ^a   Zelnak, Amelia B ^a   Mister, Donna ^a   Switchenko, Jeffrey M ^a,b   Torres, Mylin A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

21 GENE RECURRENCE SCORE; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; LOCOREGIONAL RECURRENCE; MASTECTOMY; MULTIMODALITY CANCER THERAPY; PARTIAL MASTECTOMY; RECURRENCE RISK; RISK ASSESSMENT; SCORING SYSTEM; AGED; BREAST NEOPLASMS; CANCER GRADING; DIAGNOSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SEGMENTAL MASTECTOMY; TUMOR RECURRENCE; VERY ELDERLY;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84925465232     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4252-y     Document Type: Article

References (29)

1. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.
2. Lo SS, Mumby PB, Norton J, et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol. 2010;28(10):1671–6.
3. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–34.
4. Nuyten DS, Kreike B, Hart AA, et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res. 2006;8(5):R62.
5. Kreike B, Halfwerk H, Armstrong N, et al. Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res. 2009;15(12):4181–90.
6. Connor CS, Touijer AK, Krishnan L, Mayo MS. Local recurrence following breast conservation therapy in African-American women with invasive breast cancer. Am J Surg. 2000;179(1):22–6.
7. Taghian A, Jeong J-H, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004;22(21):4247–54.
8. Jones HA, Antonini N, Hart AA, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol. 2009;27(30):4939–47.
9. Wallgren A, Bonetti M, Gelber RD, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol. 2003;21(7):1205–13.
10. Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 2011;29(21):2852–8.
11. Selz J, Stevens D, Jouanneau L, Labib A, Le Scodan R. Prognostic value of molecular subtypes, ki67 expression and impact of postmastectomy radiation therapy in breast cancer patients with negative lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2012;84(5):1123–32.
12. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol. 2008;26(5):721–8.
13. Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28(10):1677–83.
14. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320(8):479–84.
15. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89(22):1673–82.
16. Solin LJ, Gray R, Goldstein LJ, et al. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat. 2012;134(2):683–92.
17. Gonzalez-Angulo A, Barlow W, Gralow J, et al. OT1-03-01: a randomized phase III clinical trial of standard adjuvant endocrine therapy ± chemotherapy in patients (pts) with 1–3 positive nodes, hormone receptor (HR)-positive and HER2–negative breast cancer with recurrence score (RS) of 25 or less: SWOG S1007. Cancer Res. 2011;71(24 Suppl 3).
18. Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual, 7th ed. New York: Springer; 2010.
19. ®. Proceedings of the 28th SAS Users Group International Conference (SUGI) 2003.
20. Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrika. 1990;77(1):147–60.
21. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data, vol. 360. New York: Wiley; 2011.
22. Cox DR. Regression models and life tables. J R Stat Soc Series B Stat Methodol. 1972;34(2):187–220.
23. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.
24. Cheng SH, Horng CF, West M, et al. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol. 2006;24(28):4594–602.
25. Nimeus-Malmstrom E, Krogh M, Malmstrom P, et al. Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy. Breast Cancer Res. 2008;10(2):R34.
26. Sabatier R, Finetti P, Cervera N, et al. Gene expression profiling and its utility in prediction of local relapse after breast-conserving therapy in early breast cancer. Cancer Genomics Proteomics. 2011;8(4):199–209.
27. Belletti B, Vaidya JS, D’Andrea S, et al. Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin Cancer Res. 2008;14(5):1325–32.
28. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor–positive tumors. N Engl J Med. 1989;320(8):479–84.
29. Fisher B, Dignam J, Emir B, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89(22):1673–82.